Pfizer and Shanghai Pharmaceutical Partner in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer and Shanghai Pharmaceutical Partner in China


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Shanghai Pharmaceutical and Pfizer have signed a memorandum of understanding for the companies to jointly pursue potential business opportunities in China.

Shanghai Pharmaceutical is a national pharmaceutical company headquartered in Shanghai. It has three primary businesses: research and development (R&D), the manufacture and sale of pharmaceutical and healthcare products, and pharmaceutical distribution and supply-chain operations. The companies are exploring a potential cooperation for the registration, commercialization, and distribution in China of an innovative Pfizer product. In addition, the companies plan to explore future cooperation opportunities, including further distribution and commercialization, R&D activities, manufacturing, and equity-investment opportunities. The companies also expect to strengthen their existing cooperation for the promotion of Pfizer’s Prevenar (7-valent) a pneumococcal conjugate vaccine, approved for use in China for the active immunization of infants and toddlers for the prevention of invasive diseases caused by the bacterium Streptococcus pneumonia.  

“Our intent to explore a range of business opportunities with Shanghai Pharmaceutical is an example of our commitment to expand our presence in China in collaboration with the local industry,” said David Simmons, president and general manager of emerging markets and established products at Pfizer, in a Pfizer press release. “Shanghai Pharmaceutical has been one of Pfizer’s major partners in China for years and is currently our largest distribution customer in the market.”

Details of the companies’ various areas of potential cooperation under the strategic partnership will be set forth in future definitive agreements.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here